130 related articles for article (PubMed ID: 21241401)
1. Increased COX-2 expression in human vaginal epithelial cells exposed to nonoxynol-9, a vaginal contraceptive microbicide that failed to protect women from HIV-1 infection.
Zalenskaya IA; Cerocchi OG; Joseph T; Donaghay MA; Schriver SD; Doncel GF
Am J Reprod Immunol; 2011 Jun; 65(6):569-77. PubMed ID: 21241401
[TBL] [Abstract][Full Text] [Related]
2. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission.
Fichorova RN; Tucker LD; Anderson DJ
J Infect Dis; 2001 Aug; 184(4):418-28. PubMed ID: 11471099
[TBL] [Abstract][Full Text] [Related]
3. Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives.
Fichorova RN; Bajpai M; Chandra N; Hsiu JG; Spangler M; Ratnam V; Doncel GF
Biol Reprod; 2004 Sep; 71(3):761-9. PubMed ID: 15128598
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety.
Galen BT; Martin AP; Hazrati E; Garin A; Guzman E; Wilson SS; Porter DD; Lira SA; Keller MJ; Herold BC
J Infect Dis; 2007 May; 195(9):1332-9. PubMed ID: 17397004
[TBL] [Abstract][Full Text] [Related]
5. Phase I safety & preliminary acceptability of nonoxynol-9 vaginal pessary as a vaginal microbicide in low risk women in Pune, India.
Joshi S; Joglekar N; Ghate M; Unni J; Risbud A; Bentley M; Shepherd M; Bollinger R; Mehendale S
Indian J Med Res; 2003 Apr; 117():152-7. PubMed ID: 14604303
[TBL] [Abstract][Full Text] [Related]
6. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects.
Stafford MK; Ward H; Flanagan A; Rosenstein IJ; Taylor-Robinson D; Smith JR; Weber J; Kitchen VS
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Apr; 17(4):327-31. PubMed ID: 9525433
[TBL] [Abstract][Full Text] [Related]
7. Preclinical assessment of the proinflammatory potential of microbicide candidates.
Doncel GF; Chandra N; Fichorova RN
J Acquir Immune Defic Syndr; 2004 Oct; 37 Suppl 3():S174-80. PubMed ID: 16419269
[TBL] [Abstract][Full Text] [Related]
8. Anti-human immunodeficiency virus type 1 microbicide cellulose acetate 1,2-benzenedicarboxylate in a human in vitro model of vaginal inflammation.
Fichorova RN; Zhou F; Ratnam V; Atanassova V; Jiang S; Strick N; Neurath AR
Antimicrob Agents Chemother; 2005 Jan; 49(1):323-35. PubMed ID: 15616312
[TBL] [Abstract][Full Text] [Related]
9. Colposcopy: still useful in microbicide safety trials?
Mauck CK; Weiner DH; Lai JJ; Schwartz JL
Sex Transm Dis; 2012 Jun; 39(6):465-9. PubMed ID: 22592833
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of immunological markers of ovine vaginal irritation: Implications for preclinical assessment of non-vaccine HIV preventive agents.
Milligan GN; Vargas G; Vincent KL; Zhu Y; Bourne N; Motamedi M
J Reprod Immunol; 2017 Nov; 124():38-43. PubMed ID: 29054075
[TBL] [Abstract][Full Text] [Related]
11. Differentiating normal from abnormal rates of genital epithelial findings in vaginal microbicide trials.
van de Wijgert JH; Kilmarx PH; Jones HE; Karon JM; Chaikummao S
Contraception; 2008 Feb; 77(2):122-9. PubMed ID: 18226677
[TBL] [Abstract][Full Text] [Related]
12. Understanding factors that modulate HIV infection at the female genital tract mucosae for the rationale design of microbicides.
Saidi H; Jenabian MA; Belec L
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1485-97. PubMed ID: 22867060
[TBL] [Abstract][Full Text] [Related]
13. Vaginal microbicides to prevent human immunodeficiency virus infection in women: perspectives on the female genital tract, sexual maturity and mucosal inflammation.
Roberts L; Liebenberg L; Barnabas S; Passmore JA
Best Pract Res Clin Obstet Gynaecol; 2012 Aug; 26(4):441-9. PubMed ID: 22429786
[TBL] [Abstract][Full Text] [Related]
14. Establishing a Th17 based mouse model for preclinical assessment of the toxicity of candidate microbicides.
Li LZ; Yang Y; Yuan SH; Wan YM; Qiu C; Feng YL; Xu JQ; Zhang XY
Chin Med J (Engl); 2010 Dec; 123(23):3381-8. PubMed ID: 22166518
[TBL] [Abstract][Full Text] [Related]
15. Study of side-effects of vaginal microbicide.
Newsl Womens Glob Netw Reprod Rights; 1994; (46):15. PubMed ID: 12288399
[TBL] [Abstract][Full Text] [Related]
16. Seminal plasma induces prostaglandin-endoperoxide synthase (PTGS) 2 expression in immortalized human vaginal cells: involvement of semen prostaglandin E2 in PTGS2 upregulation.
Joseph T; Zalenskaya IA; Sawyer LC; Chandra N; Doncel GF
Biol Reprod; 2013 Jan; 88(1):13. PubMed ID: 23153564
[TBL] [Abstract][Full Text] [Related]
17. Nonoxyl-9 and women's struggle against HIV.
Gilmour E
AIDS Anal Afr; 1996 Oct; 6(5):14. PubMed ID: 12347429
[TBL] [Abstract][Full Text] [Related]
18. Over-the-counter vaginal contraceptive and spermicide drug products containing nonoxynol 9; required labeling. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2007 Dec; 72(243):71769-85. PubMed ID: 18159651
[TBL] [Abstract][Full Text] [Related]
19. Vaginal microbicides needed for female-controlled prevention.
Contracept Technol Update; 1999 Mar; 20(3):25-7. PubMed ID: 12321962
[TBL] [Abstract][Full Text] [Related]
20. Biocompatibility of solid-dosage forms of anti-human immunodeficiency virus type 1 microbicides with the human cervicovaginal mucosa modeled ex vivo.
Trifonova RT; Pasicznyk JM; Fichorova RN
Antimicrob Agents Chemother; 2006 Dec; 50(12):4005-10. PubMed ID: 17030562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
